Advances in Intra-abdominal Sepsis: What Is New?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases
Link
http://link.springer.com/content/pdf/10.1007/s11908-015-0497-2.pdf
Reference23 articles.
1. Shirah GR, O’Neill PJ. Intra-abdominal infections. Surg Clin N Am. 2014;94:1319–33. This important multicenter, double-blind, randomized controlled trial describes the results of administering a novel antibiotic, ceftolozane/tazobactom, to cIAI patients, when compared to the current gold standard.
2. Solomkin JS et al. Diagnosis and management of complicated intra-abdominal infections in adults and children. guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;50. This is a multicenter, retrospective study evaluating different levels of procalcitonin and the role of procalcitonin in driving duration of antibiotic therapy. There is increasing evidence that procalcitonin correlates with disease severity.
3. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect. 2010;11:79–109.
4. Sartelli M et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37.
5. Solomkin J et al. Ceftolozane/tazobactum plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–71. An important prospective, double-blind non-inferiority trial randomizing patients to ceftolozane/tazobactam plus metronidazole versus meropenem. The outcomes demonstrate that ceftolozame/tazobactam is non-inferior, even in patients with multi-drug resistant organisms.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians;Pharmaceuticals;2022-04-12
2. Appropriate Antimicrobial Therapy in Critically Ill Patients;Hot Topics in Acute Care Surgery and Trauma;2017-06-23
3. Practical Approaches to Definitive Reconstruction of Complex Abdominal Wall Defects;World Journal of Surgery;2015-11-19
4. Intra-abdominal sepsis;Surgery (Oxford);2015-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3